The National Heart, Lung and Blood Institute has recently invested $11.6 million into stem cell based regenerative research being conducted at the Temple University School of Medicine. Given the increased incidence of heart disease in recent years, stem cell based treatments are emerging as an optimal method of treatment, though there are still a few hurdles these treatments must overcome in order to be at their optimal effectiveness. Many of the challenges with current stem cell treatments for heart disease are due to the age of the patients and their age-related ailments. Obtaining stem cells for treatment at an older age reduces the stem cells’ efficacy - compared to younger cells, and also impacts the yield; often resulting in an insufficient number of cells for treatment.
Dr. Raj Kishore, Professor of Pharmacology and Medicine at Temple University, commented "In many cases, the stem cells themselves were injured by inflammation in the heart following injection or were not functioning optimally, having been weakened from disease, such as diabetes, or age." The findings lend evidence to the wisdom of planning ahead to secure the “biological insurance” found in younger stem cells. By cryopreserving younger stem cells, patients would greatly increase their odds of success with future stem cell-based regenerative treatments.
To learn more about stem cells, and how families can bank their own valuable stem cells by recovering the very powerful dental pulp stem cells during routine dental procedures; such as wisdom teeth extractions or the during the loss of baby teeth, visit StemSave or call 877-783-6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here.